Compare DexCom, Inc. (DXCM) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Boston Beer Company Inc — how do they compare? DexCom, Inc. trades at $77.51 (market cap $28.06B), while Boston Beer Company Inc trades at $174.5 (market cap $1.77B). The key difference: DexCom, Inc. is far larger — about 15.9× Boston Beer Company Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | SAM | |
|---|---|---|
Market Cap | $28.06B | $1.77B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $260.05 |
52-Week Low | $54.84 | $161.08 |
Enterprise Value | $27.03B | $1.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Boston Beer Company (SAM) trades at $173.89, up 3.04% on the day, with a bearish technical signal and mixed fundamentals. The stock shows a P/E of 22.66 and P/S of 0.94, with recent earnings beating expectations in Q3 and Q4 2025 but missing in Q1 2026. Operating cash flow remains positive at $270M for 2025, though net income margin turned negative to -3.15% in 2026 projections. Analyst consensus is 'Hold' with a $213.50 price target, representing 22.8% upside potential.
The outlook presents a mixed picture: valuation appears reasonable with solid cash generation, but profitability concerns and bearish technicals create headwinds. Key opportunities include continued 'Beyond Beer' expansion and cost-saving initiatives, while risks involve volume pressure on key brands and execution challenges in a competitive beverage market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
